EUVIMEDSkopri EUVIMED
Qualitative StudieOpen access · CC BY-NC 4.0

Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists

Miro Korppas iD, Miia Tiihonen iD, Marika Buch Lund, Kirsi Kvarnström iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70106 ↗

At a glance

Qualitative Studie in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Miro Korppas and 3 co-authors. Institution: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Major MEDLINE topics: Deprescriptions, Benzodiazepines, Pharmacists, Physicians. Cited 2 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

While deprescribing benzodiazepines and related drugs (BZRDs) is crucial for preventing prolonged use and their associated adverse effects, it presents challenges from a healthcare perspective, because of limited resources and time. Recently, a pharmacist‐led deprescribing of BZRDs in the treatment of insomnia was introduced in Helsinki's primary care health centres. To explore pharmacists' and physicians' insights, qualitative semi‐structured interviews were conducted via Microsoft Teams with physicians and pharmacists involved in a pharmacist‐led deprescribing. The interviews were recorded, transcribed verbatim and analysed abductively. A total of four pharmacists and four physicians from four health centres participated in this study. Pharmacist‐led deprescribing was perceived as having positive outcomes and as being efficient, particularly in saving physicians' time and resources. Various patient‐related facilitators and barriers were identified, with patient motivation and willingness being the most cited. Suggestions for improvement included establishing clear criteria for deprescribing, clarifying the roles in the process flow, providing enhanced deprescribing guidance and educational materials and enhancing the patient‐centred approach by actively involving patients in the decision‐making process and considering the patient's overall situation. Overall, the pharmacist‐led model was seen as a promising and resource‐efficient approach to deprescribing BZRDs in primary care health centres.

Subjects

MeSH terms (MEDLINE)

DeprescriptionsBenzodiazepinesPharmacistsPhysiciansPharmaceutical ServicesInterviews as TopicQualitative ResearchHumansAttitude of Health PersonnelPractice Patterns, Pharmacists'Professional RoleMaleFemaleAdultMiddle Aged

Author keywords

benzodiazepinesbenzodiazepine‐related drugsdeprescriptionpharmacist‐ledprimary care

Substances

Benzodiazepines

Authors and institutions

  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • HUS Pharmacy, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Health and Social Services, Helsinki, Finland.

ORCID profiles: Miro Korppas, Miia Tiihonen, Kirsi Kvarnström

Cite

APA

Korppas, M., Tiihonen, M., Buch Lund, M., & Kvarnström, K. (2025). Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70106

Vancouver

Korppas M, Tiihonen M, Buch Lund M, Kvarnström K. Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70106

BibTeX
@article{Korppas2025,
  author = {Korppas, Miro and Tiihonen, Miia and Buch Lund, Marika and Kvarnström, Kirsi},
  title = {Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70106}
}
Start for free →